Skip to Main Content

Paper Details

A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS.
Neurotherapeutics
1
2023
Author NameAffiliation
Kathryn C FitzgeraldJohns Hopkins University School of Medicine
Kathryn C Fitzgerald
Peter A CalabresiJohns Hopkins University School of Medicine
Peter A Calabresi
  • 1 - 4

Datasets

Release 1.2